King of Prussia-based CSL Behring provided an update earlier this week on its multiple efforts – both independent and in collaborations – to battle COVID-19, writes John George for the Philadelphia Business Journal.

The biopharmaceutical company got an early start in the fight against the deadly virus because it received early reports from its manufacturing plant in Wuhan, China.

The company responded quickly, beginning work on a vaccine and looking at other internal products that could potentially help those already infected.

Then in April, the company teamed up with other plasma-focused biopharmaceutical companies to potentially find a therapy derived from the blood of recovered patients.

In its latest update, the company said that the Covid-19 Plasma Alliance had enrolled its first clinical trial participants for a late-stage experimental hyperimmune therapy study earlier this month.

Additionally, CSL Behring is conducting a mid-stage study to assess the safety and efficiency of one of its existing treatments for severe respiratory distress in COVID-19 patients. It is also working with AstraZeneca to manufacture around 30 million doses of its vaccine candidate, if successful.

Read more about CSL Behring at the Philadelphia Business Journal by clicking here.

You Might Also Like

King of Prussia-based CSL Behring Evaluating Experimental Drug for COVID-19

FDA Places Clinical Hold on Plymouth Meeting’s Inovio’s COVID-19 Vaccine

Philadelphia Magazine: Latest Addition to King of Prussia Mall is COVID-19 Store